The International Nonproprietary Name (INN) of the medicinal product is an inactivated emulsion vaccine against Newcastle disease, infectious bronchitis in chickens (multi-strain), infectious bursal disease, and metapneumovirus infection in birds.
“The vaccine is derived from the extraembryonic fluid of chicken embryos infected with Newcastle disease viruses (LaSota Strain), infectious bronchitis of chickens (Chapaevsky strain Massachusetts-type, ARRIAH793/B strain 793/B serotype, ARRIAH RF08-10 QX strain QX-type), homogenate of chicken embryo carcasses infected with infectious bursal disease virus (BG strain), and culture liquid of a Vero cell culture infected with avian metapneumovirus (PV03-B strain). It is rendered inactive through the incorporation of dimer aminoethylethyleneimine, supplemented with thimerosal as a preservative. Additionally, the oil adjuvant, Montanide ISA 70 VG or an analogue, is included in a proportion of 30:70,” stated the institution.
The scientists have elucidated that the vaccine is specifically designed to avert Newcastle disease, infectious bronchitis in chickens resulting from diverse serotypes of the virus, infectious bursal disease, and metapneumovirus infection prevalent in breeding and commercial poultry farms employing various farming methodologies.
Following a single administration, the vaccine triggers the development of an immune response in chickens against the mentioned infections within a 28-day period. The immunity persists for a duration of 12 months.
The drug is supplied in the form of injectable emulsions.
